SHEL.UK

2,884.5

-1.1%↓

SHEL.UK

2,884.5

-1.1%↓

SHEL.UK

2,884.5

-1.1%↓

SHEL.UK

2,884.5

-1.1%↓

SHEL.UK

2,884.5

-1.1%↓

Search

Smith & Nephew PLC

Fermé

1,299.5 1.48

Résumé

Variation du prix de l'action

24h

Actuel

Min

1280

Max

1306

Chiffres clés

By Trading Economics

Revenu

296M

Ventes

3B

P/E

Moyenne du Secteur

31.207

25.238

BPA

0.429

Rendement du dividende

2.99

Marge bénéficiaire

9.895

Employés

17,000

EBITDA

723M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+13.87% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.99%

4.00%

Prochains Résultats

2 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.9B

11B

Ouverture précédente

1298.02

Clôture précédente

1299.5

Smith & Nephew PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 févr. 2026, 23:47 UTC

Actions en Tendance

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 févr. 2026, 22:59 UTC

Résultats
Acquisitions, Fusions, Rachats

Grab Holdings to Buy U.S.-Based Stash Financial

11 févr. 2026, 23:54 UTC

Résultats

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 févr. 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 févr. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 févr. 2026, 23:49 UTC

Résultats

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 févr. 2026, 23:45 UTC

Résultats

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 févr. 2026, 23:42 UTC

Résultats

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 févr. 2026, 23:41 UTC

Résultats

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 févr. 2026, 23:40 UTC

Résultats

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 févr. 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 févr. 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 févr. 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 févr. 2026, 22:59 UTC

Résultats

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 févr. 2026, 22:59 UTC

Résultats

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 févr. 2026, 22:59 UTC

Résultats

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 févr. 2026, 22:58 UTC

Résultats

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 févr. 2026, 22:57 UTC

Résultats

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 févr. 2026, 22:54 UTC

Résultats

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 févr. 2026, 22:53 UTC

Résultats

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 févr. 2026, 22:47 UTC

Résultats

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 févr. 2026, 22:47 UTC

Résultats

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 févr. 2026, 22:23 UTC

Résultats

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 févr. 2026, 22:22 UTC

Résultats

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 févr. 2026, 22:22 UTC

Résultats

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 févr. 2026, 22:19 UTC

Résultats

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 févr. 2026, 22:18 UTC

Résultats

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 févr. 2026, 22:18 UTC

Résultats

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 févr. 2026, 22:18 UTC

Résultats

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 févr. 2026, 22:16 UTC

Résultats

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparaison

Variation de prix

Smith & Nephew PLC prévision

Objectif de Prix

By TipRanks

13.87% hausse

Prévisions sur 12 Mois

Moyen 1,465.5 GBX  13.87%

Haut 1,650 GBX

Bas 1,290 GBX

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

8 ratings

5

Achat

3

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat